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Administration (FDA) Investigational Device Exemption
(IDE) clinical trial in 1989.11 More than 500 patients
received the device. ASD closure was successful in the
majority of patients with some procedure-related mor-
bidity, no midterm morbidity, and no mortality. Success
was most likely for central secundum defects less than 20
mm in diameter. As enthusiasm was building for the
device, incidental breaks in the metal arms were noted.
Although few, if any, serious sequelae developed from
these breaks, it was clear that a material and design
change was necessary and the device was withdrawn.
Despite this design failure, this initial clinical experience
indicated that many ASDs could be safely and effective-
ly closed in the catheterization laboratory. Another ASD
closure device, the Sideris buttoned occluder (Custom
Medical Devices, Amarillo, Tex), has been implanted in
more than 400 patients with similar results.12 At least
three other ASD occluder devices (Das AngelWings
device13 [Microventa Corp, White-Bear Lake, Minn],
ASDOS device14 [Osypka Corporation, Rheinfelden,
Germany], and Amplatzer device15 [AGA Medical Corp,
Golden Valley, Minn]) have been introduced and are
being evaluated in clinical trials. Because of FDA restric-
tions, most of the experience with these newer devices
has been obtained outside of the United States. In
September of 1999, however, the FDA granted approval
for the selective use of the latest generation of the
clamshell device, the CardioSEAL Septal Occluder
(Nitinol Medical Technology, Inc, Boston, Mass).
Application of the device was limited to the closure of
Fontan fenestrations and apical ventricular septal defects.
In January of 2000 the closure of a patent foramen ovale
for paradoxic embolization was added to the acceptable
indications. It may not be long before the FDA adds
small centrally located secundum ASDs to this list. 
Thus, the writing is on the wall! Transcatheter closure
is becoming an accepted technique for closure of patent
foramen ovales and some ASDs. Because it can be per-
formed without general anesthesia, without cardiopul-
monary bypass, and without an incision, the technique
must be considered an attractive alternative to conven-
tional surgical closure. Although the cost of the device
and the implantation facilities may be similar to those
of surgical closure, hospitalization is shortened or elim-
inated and time off from work is greatly reduced. Let’s
admit it. Transcatheter ASD closure will be the best
approach for some patients. 
The era of open heart surgery began with a variety ofingenious techniques directed at closure of the secun-
dum atrial septal defect (ASD).1-4 Indeed, the first suc-
cessful application of cardiopulmonary bypass was for
this purpose.5 Direct vision intracardiac surgery owes its
origins to the ASD. Over the past half century surgical
closure of a secundum ASD has become a low-risk and
highly successful procedure.6,7 In addition to being bread
and butter for the heart surgeon, ASD closure has become
a valuable procedure for introducing the cardiothoracic
resident to true “open” heart surgery. Until recently, car-
diovascular surgeons have felt privileged and (maybe,
self-importantly) exclusively qualified to close these
defects. Now our turf is being challenged once again by
some bright and innovative nonsurgeons, the interven-
tional cardiologists. Our cardiology colleagues, demon-
strating ingenuity not unlike that of our predecessors in
cardiac surgery, have developed techniques to close inter-
atrial communications with a catheter! Is transcatheter
ASD closure a safe and reasonable approach? Is it a threat
to our livelihood or our ability to train residents? What
role should we play in its introduction?
The first successful transcatheter closure of an ASD
occurred a quarter of a century ago. Thus, it is somewhat
surprising that the technique is only now becoming an
alternative to surgery. The initial report in 1976 by King
and Mills 8 demonstrated the feasibility of the approach,
but the requirement for a very large (23F) delivery
catheter precluded its application to the pediatric popula-
tion. In the mid-1980s, based on a device initially
designed by William Rashkind,9 James Lock and C.R.
Bard, Inc (Murray Hill, NJ) applied the double-umbrella
concept to develop the clamshell ASD occlusion
device,10 which could be introduced through an 11F
femoral sheath. The Bard clamshell was introduced into
a prospective nonrandomized multicenter Food and Drug
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Acceptance of the value of this technique, however,
does not relieve the surgeon of an important role in its
introduction into our local or regional cardiovascular pro-
grams. A close working relationship between the surgeon
and the interventionalist will permit successful and safe
application of this technique. The surgeon’s role contin-
ues to be that of patient advocate, recognizing favorable
and unfavorable anatomy, and participating in the selec-
tion of patients for the transcatheter approach. Ostium
primum and sinus venosus ASDs, as well as large secun-
dum defects with limited septal margins, are more suit-
able for closure under direct vision with cardiopulmonary
bypass. Therefore, patients will continue to be available
for the training of our residents. The other role the sur-
geon must play is that of backup in case of failure or
device embolization. As always, the surgeon remains
uniquely qualified for dealing with failures in the
catheterization laboratory. The accompanying article by
Berdat and associates16 describes the experience of a sur-
gical team dealing with complications of transcatheter
closure techniques.
The fact that complications have occurred with these
techniques has not and should not dissuade its proponents
from continuing to apply the devices. With any new tech-
nique a certain experiential learning curve is expected. In
the present article 8% of patients required surgical inter-
vention, an incidence that is likely to decrease with time.
The average ASD diameter of 25 mm for patients coming
to surgical intervention supports the concept that defect
size is an important factor in selecting patients for device
closure. Lessons learned from their experience are well
described by the authors. The most common failure in
their experience was malposition of the device resulting
in a residual ASD, further evidence suggesting a problem
with patient selection. The make of septal occluder may
also be a factor, but comparative data in this regard are not
yet available. More important, when surgery is required
for a complication, conventional surgical techniques are
successful with low morbidity. On the basis of the expe-
rience from Bern, it could be cogently argued that
although surgery became necessary in some cases, tran-
scatheter procedures saved more than 90% of patients
from an open heart operation. The one death in the series,
resulting from perforation of the left ventricle during per-
cutaneous attempts to recover a dislocated device, should
serve as an important warning that this new technique
does have potential for mortality and must not be taken
lightly. As transcatheter ASD closure is introduced into
our medical communities, let us continue to foster a care-
ful and deliberate collaboration between surgeon and
interventionalist.
Finally, let us not forget that the ultimate success of any
technique must be evaluated over the long term. A
promising early result does not guarantee a favorable late
outcome. Our own experience with the Ionescu-Shiley
and convexo-concave Björk-Shiley valve prostheses
attests to the importance of continued follow-up and crit-
ical evaluation for years to come. Surgical closure of an
ASD has stood the test of time. Will the same be true for
transcatheter closure?
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